Back to top

gene-editing: Archive

Zacks Equity Research

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

INONegative Net Change CRMDNegative Net Change KNSANegative Net Change PGENNegative Net Change